<div id="readability-page-1"><p>Optivise Advisory Services LLC bought a new stake in shares of  Eli Lilly and Company (NYSE:LLY - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor  bought 1,954 shares of the company's stock, valued at approximately $1,731,000. Eli Lilly and Company comprises approximately  0.9% of Optivise Advisory Services LLC's portfolio, making the stock its 27th biggest holding.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance</li></ul><p>A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Virtu Financial LLC purchased a new position in  Eli Lilly and Company during the first quarter worth $2,138,000.  Chesley Taft &amp; Associates LLC grew its holdings in  Eli Lilly and Company by 5.4% during the 2nd quarter. Chesley Taft &amp; Associates LLC now owns 22,553 shares of the company's stock valued at $20,419,000 after purchasing an additional 1,163 shares during the last quarter.  OMNI 360 Wealth Inc. purchased a new stake in  Eli Lilly and Company in the 2nd quarter worth about $239,000.  Long Run Wealth Advisors LLC bought a new stake in  Eli Lilly and Company in the second quarter worth about $209,000.  Finally, Essex Financial Services Inc. boosted its position in shares of  Eli Lilly and Company by 5.8% during the second quarter. Essex Financial Services Inc. now owns 28,183 shares of the company's stock valued at $25,517,000 after buying an additional 1,556 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors. </p><h2>Insider Transactions at Eli Lilly and Company</h2><p>In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own  0.13% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>MarketBeat Week in Review – 11/4 - 11/8</li></ul><p>A number of research firms have weighed in on LLY. Truist Financial increased their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, October 10th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a &#34;buy&#34; rating for the company in a report on Monday, November 4th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, August 14th. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an &#34;outperform&#34; rating and a $1,100.00 price target for the company. Finally, Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an &#34;outperform&#34; rating and a $1,000.00 price objective on the stock. Four analysts have rated the stock with a hold rating and seventeen have issued  a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company  has an average rating of &#34;Moderate Buy&#34; and an average price target of $1,007.94.</p><p><b>Get Our Latest Stock Analysis on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Trading Down 0.3 %</h2><ul><li>How Altimmune Could Grab a Big Chunk of the GLP-1 Market</li></ul><p>Shares of Eli Lilly and Company stock opened at $748.01 on Friday. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The firm's 50 day simple moving average is $865.01 and its two-hundred day simple moving average is $869.01. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $710.10 billion, a price-to-earnings ratio of 80.87, a PEG ratio of 2.84 and a beta of 0.43. </p><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business's revenue was up 20.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS.  Analysts predict that  Eli Lilly and Company will post 13.2 EPS for the current year. </p><h2>Eli Lilly and Company Announces Dividend</h2><p>The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%. </p><h2>About Eli Lilly and Company</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>About the Markup Calculator</li><li>Vertiv’s Cool Tech Makes Its Stock Red-Hot</li><li>Roth IRA Calculator: Calculate Your Potential Returns</li><li>MarketBeat Week in Review – 11/18 - 11/22</li><li>3 Grocery Stocks That Can Help Take a Bite Out of Inflation </li><li>2 Finance Stocks With Competitive Advantages You Can't Ignore</li></ul><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ I hate to say I told you so <span><span>(From WealthPress)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDQ5Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDQ5Mg"/></p><h2>Should you invest $1,000 in Eli Lilly and Company right now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Optivise Advisory Services LLC has made a new investment of approximately $731,000 in Eli Lilly and Company (NYSE: LLY), acquiring 1,954 shares. This investment represents about 0.9% of Optivise's portfolio, ranking as its 27th largest holding. Other institutional investors have also adjusted their positions in LLY, with significant purchases in recent quarters. Eli Lilly's stock has received multiple upgrades from analysts, with a consensus rating of "Moderate Buy" and an average price target of $1,007.94. The company's recent earnings report showed an EPS of $1.18, missing estimates by $0.34.</p>

Optivise Advisory Services LLC Makes New $1.73 Million Investment in Eli Lilly and Company (NYSE:LLY)